| Name | Title | Contact Details |
|---|
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.
Bank of George emerged with a new brand celebrating our technological advancements in the digital space – GBank! We are proud of our improved digital banking and mobile apps for both your personal and business accounts. With increased functionality and efficiency, we know you will love the new GBank. And as tech advances, so will we. We will never lose sight of the core values that have made us your chosen community bank as we grow. Our goal is to give our clients the highest level of service and care at all times. When they look back and assess their relationship with our institution, the total of all the interactions along their banking journey with GBank equals Your Best Banking Experience Ever!® But it doesnt stop there. Our goal is always to give our colleagues that same level of service and care.
Pendrick Capital Partners is one of the largest HEALTHCARE debt buyers in the USA providing additional revenue streams to all our clients. Our management team is comprised of industry veterans with over 80 years of combined knowledge. We bring core expertise to all consumer debt segments in our underwriting and servicing processes. We hold ourselves to the highest standards and take pride in our business relationships. Our commitment to customer service is unmatched in the industry, just ask for our references. The sale of aged A/R among HEALTHCARE providers has become much more mainstream over the last 10 years. During the last 3 years, Pendrick Capital Partners has purchased over 55 million accounts with a face value of over $16 billion. These portfolios represent patient accounts at ER physician groups, ambulance companies and hospitals. The desire of providers to implement a profitable, compliant, and sensible solution to their revenue cycle challenges and cash acceleration needs has never been greater. With the right partner, the impact of selling should be no different than the impact of using contingency collection agencies to recover delinquent accounts. In many cases, clients have informed us that this practice has enhanced overall collections, as it creates an expectation of payment within their patient bases. Pendrick Capital Partners recognizes the important role that physicians, clinics and hospitals play in local communities and conducts its business with the highest degree of professionalism and respect for patients and clients. Careful due diligence helps us understand an organization`s unique needs and ensures that our tailored collection efforts meet our clients expectations prior to starting a relationship. We do not resell accounts and strongly recommend that any healthcare provider who is concerned about patient and community relations makes a no-resale provision a non-negotiable part of its business agreement with any debt buyer.
CarbonBuilts Carbon XPrize-winning technology enables the production of ultra low-carbon concrete products, driving gigatonne-scale greenhouse gas reductions through the cost-effective mineralization of carbon dioxide. Our revolutionary approach reduces overall carbon dioxide emissions by 70-100%+, with no compromise on price, performance, or plant operations.